1049 / 1708
AREN0532: Stage III FH Tumors
•
583 eligible patients met COG Stage III criteria; 40 pts
excluded from analysis secondary to combined LOH
1p and 16 q
•
All received DD4A chemotherapy (vincristine,
dactinomycin, doxorubicin)
•
Median follow-up: 42 months